INSUBCONTINENT EXCLUSIVE:
The pharma major had reported a profit of Rs 312.50 crore in the corresponding quarter last year.
ETNow poll estimated Rs 373-crore profit
for the quarter under review.
Revenues inched lower to Rs 3,534.90 crore in Q4FY18 over Rs 3,554.20 crore last year
ETNow poll had predicted sales of Rs 3,554 crore.
The board of the company recommended a final dividend of Rs 20 per equity per share on
face value of Rs 5 each for financial year 2017-18
Expenses on research and development (RD) stood at Rs 435 crore in Q4FY18, which was 12.30 per cent of total revenues
Gross margin came in at 53.50 per cent during the quarter against 56.30 per cent in Q3FY18 and 51.20 per cent in Q4FY17.
Commenting on the
This was mainly on account of continuing headwinds in the US market and a temporary drop in sales in Russia, attributable to a shift in the
